Dr. Xavier Leleu (Hopital Claude Huriez, CHRU Lille, France) discusses using Hevylite® to monitor hypogammaglobulinemia, a predictor of response to therapy in multiple myeloma. The results were presented at the 56th American Society of Hematology (ASH) Annual Meeting. ASH 2014 abstract 3383.
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM
West Building, Level 1 (Moscone Center)
Guillemette Fouquet, MD1*, Susanna Schraen, MD2*, Jean-Luc Faucompré, MD3*, Lionel Karlin4*, Margaret Macro, md5*, Cyrille Hulin, md6*, Brigitte Onraed, MD2*, Laurent Garderet, MD7, Murielle Roussel, MD8*, Bertrand Arnulf, MD, PhD9*, Brigitte Pegourie, MD10*, Brigitte Kolb11*, Anne-Marie Stoppa, MD12, Sabine Brechiniac, MD13*, Gerald Marit14*, Claire Mathiot, MD15*, Anne Banos, MD16*, Mourad Tiab, MD17*, Mamoun Dib18*, Jean-Gabriel Fuzibet, MD19*, Marie Odile Petillon, MD1*, Philippe Rodon20, Marc Wetterwald, MD, PhD21*, Bruno Royer, MD22*, Laurence Legros, MD, PhD23*, Lotfi Benboubker, MD, PhD24*, Olivier Decaux25*, Denis Caillot, MD26*, Martine Escoffre-Barbe, MD25*, Jean Paul Fermand, MD27, Philippe Moreau, MD28*, Michel Attal29, Hervé Avet-Loiseau, MD, PhD30, Thierry Facon, MD31, Xavier Leleu, MD1 and Stephen Harding, PhD32
1Service des Maladies du Sang, Hopital Claude Huriez, CHRU Lille, Lille, France
2Service de biochimie proteine, Hôpital Huriez, CHRU Lille, LILLE, France
3HOPITAL HURIEZ, LILLE, France
4Immuno-Hematology Unit, Paris, France
5hematology department, university hospital of caen, caen, France
6HOPITAL, NANCY, France
7Hematology, Centre Hospitalier Universitaire Hopital St-Antoine, Paris, France
8Institut Universitaire du Cancer and University Hospital, Hematology department, Toulouse, France
9Saint Louis Hosp., Paris, France
10Centre Hospitalier Regional Universitaire, Grenoble, France
11Hôpital Robert Debré, CHU, REIMS, France
12Hematology, Institut Paoli Calmettes, Marseille, France
13CHU Avicennes, APHP, Paris, France
14Service d'Hématologie et de Thérapie Cellulaire, University Hospital of Bordeaux, Pessac, France
15Institut Curie, APHP, paris, France
16HOPITAL, BAYONNE, France
17hematology, university hospital, la roche sur yon, France
18CHRU Hopital du bocage, Dijon, France
19CH de l'Archet, Nice, France
20CH Blois, Coulanges, France
21CHD Dunkerque, Dunkerque, France
22Hôpital Sud, CHU, Amiens, France
23Hematology department, Hopital de l'Archet, Nice, France
24CHU Tours Hopital Bretonneau, Tours, France
25Hematology, CHU Rennes, Rennes, France
26Hematology Department, CHU de Dijon - Hospital `Le Bocage`,, Dijon, France
27Service d'Immuno-Hématologie, Hôpital Saint Louis, Paris, France
28CH BRETAGNE SUD SITE SCORFF, LORIENT CEDEX, France
29Hématologie Clinique, CHU Purpan, Toulouse, France
30University Hospital of Nantes, Nantes, France
31Hopital Claude Huriez, CHRU Lille, Lille, France
32The Binding Site Group Ltd, Birmingham, United Kingdom
Background. The depth of Hypogammaglobulinemia has been related to adverse prognosis in myeloma for decades, but most importantly, it has been suggested that its recovery following treatment was associated with good outcome and prolonged survival. However, none of the traditional techniques has allowed a precise measurement of isotype-matched (i.e. concentrations of IgGκ in an IgGλ myeloma patient) hypogammaglobulinemia. Recently, a new test quantifying paired clonal and non-clonal immunoglobulins (heavy/light chains HLC i.e. IgGκ/IgGλ) in serum was developed. Here we aim to assess the new HLC assays as tools to measure Hypogammaglobulinemia, and potentially replace traditional techniques for the monitoring of patients with myeloma.
Materials and methods. 107 (59 IgGκ, 29 IgGλ, 12 IgAκ, 7 IgAλ) myeloma patients treated with pomalidomide and dexamethasone in two IFM studies (IFM 2009-02 in end-stage RRMM, and IFM 2010-02 in del17p and t(4;14) RRMM ) were included. The criteria for selection were that patients had measurable intact immunoglobulin myeloma according to IMWG criteria (M spike ≥10g/L), using serum and/or urine protein electrophoresis, with exclusion of patients solely measurable on UPEP and sFLC. All sera were collected centrally before initiation of treatment and sequentially every cycle until progression. Hevylite® (HLC) was measured in the biology laboratory of CHRU of Lille (France). For each patient we have measured the clonal isotype HLC level, and the corresponding non-clonal paired isotype HLC level, e.g. for IgAκ myeloma, the IgAλ non-clonal paired isotype. (Normal ranges: IgGκ 3.84-12.07, IgGλ 1.91-6.74 and IgGκ/IgGλ 1.12-3.21; IgAκ 0.57-2.08, IgAλ 0.44-2.04 and IgAκ/IgAλ 0.78-1.94 g/L).
Results. Overall, 98 (92%) patients had an abnormal suppressed uninvolved HLC level at baseline with suppression being more common in IgG than IgA patients (95% v 73%, p<0.001), and 94 (87%) at the time the greatest response was reached (IgG 90% > IgA 77%), meaning that the vast majority of patients had not recovered from hypogammaglobulinemia at the time of best response. The median uninvolved IgG and IgA HLC concentrations at baseline were 0.62 and 0.2 g/L respectively (range: 05-6.9; 0.01-5.6). At best, response levels reached were 0.53 and 0.24g/L respectively (0.01-5.6; 0.01-7.4). Interestingly, more patients had recovered in the IFM 2009-02 study compared to the IFM2010-02 study, essentially different in the number of prior lines of therapy (3 and 9, respectively).
We then sought to understand the relationship with response to therapy. We noted that very few patients’ hypogammaglobulinemia levels normalized completely, nor did their uninvolved paired isotype HLC levels normalize. However, we found that 55% of responders (IMWG) had improved levels (by at least 20%) of the uninvolved paired isotype HLC compared to 18.5% of the non-responders (p=0.001). Similarly, an improvement of at least 50% in the levels of uninvolved paired isotype HLC was achieved by 35% of responders compared to 13% of non-responders, respectively (p=0.013); an improvement of 75% was reached by 22.5% of responders and 7.4% of non-responders (p=0.028). This data strongly correlated to the depth of response, since, for example, 75% of patients in VGPR or better had improved levels of uninvolved paired isotype HLC by 50% at the time of greatest response, compared to 31% for PR and 13% for SD (p=0.005). Similar correlations were seen for 20% (p<0.0001) and 75% (p=0.16) recoveries.
Conclusion. The mechanism of immunosuppression in myeloma patients is poorly understood. Here we have shown for the first time that isotype-matched hypogammaglobulinemia correlates to depth of response. Hypogammaglobulinemia is important to assess not only because of its greater risk of infectious complications, often severe in myeloma, but also as it plays a predictive role in occurrence of response and more importantly depth of response. Future studies are needed to unravel the relationship between debulking of tumor cells and correction of hypogammaglobulinemia; in other words, is repopulating of the marrow with normal B cells associated to better outcome, and how does this affect the homeostasis of the bone marrow in its ability to support tumour cells.
ABOUT XAVIER LELEU, MD, PhD
Dr. Xavier Leleu is the Head of the Myeloma Clinic and Head of the Department of Hematology at Hôpital La Mileterie, part of the academic hospital of Poitiers, France. He is actively involved in numerous national and international clinical trials as an investigator and coordinator. Dr. Leleu is a frequent speaker at national and international congresses and is a reviewer or a member of the editorial board of several hematology journals. He is actively involved in the Intergroupe Francophone du Myélome. Visit Dr. Xavier Leleu’s full biography.